Gene · 10219
KLRG1: killer cell lectin like receptor G1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. KLRG1: killer cell lectin like receptor G1. Genes, record 10219. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10219
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q96E93 | Killer cell lectin-like receptor subfamily G member 1 | 195 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents43
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026082951 A | 2026-05-19 | 5 | Q96E93 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 50777 | Q96E93 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 127 | Q96E93 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 15256 | Q96E93 | Espacenet |
| EP 4619424 A2 | 2025-09-24 | 14 | Q96E93 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2320 | Q96E93 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2320 | Q96E93 | Espacenet |
| JP 2025092554 A | 2025-06-19 | 6 | Q96E93 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 15256 | Q96E93 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 127 | Q96E93 | Espacenet |
1 to 10 of 43
See all 43 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants2,977
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | KLRG1 papers | Newest fiscal year |
|---|---|---|---|
| U19AI082630 | Durable Alteration of the Human Immune system after Infection or Immunotherapy | 24 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 22 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 21 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 14 | 2025 |
| R01AI066232 | Regulation of memory CD8 T cell development | 13 | 2025 |
| R01AI100874 | The natural killer cell response against mouse cytomegalovirus infection | 13 | 2025 |
| U19AI057266 | Vaccine and Infection Induced Immunity in the Young and Aged | 13 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 12 | 2025 |
| U01AI095608 | Regulation of mucosal immunity by neuronal pathways | 12 | 2025 |
| P01AI108545 | Synergies among inhibitory receptors in tolerance and disease | 11 | 2025 |
1 to 10 of 2,977Source NIH's project files
See all 2,977 nih grantsPapers3,260
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Impact of Aerobic Exercise on Circulating T-Cells and NK-Cells in Colorectal Cancer Survivors: A Secondary Analysis of a Randomized Trial. | Cancer Control | 2026 | 42808444 | PubTator, text mining | PubMed |
| CD43 is a checkpoint against KLRG-1+CD49dhi effector CD8+ T cell formation. | Transpl Immunol | 2026 | 42785691 | PubTator, text mining | PubMed |
| Myositis with nemaline rods: Clinical features and treatment outcomes. | J Neurol Sci | 2026 | 42700620 | PubTator, text mining | PubMed |
| Inclusion body myositis: new insights into pathogenesis and therapeutic perspectives. | Curr Opin Rheumatol | 2026 | 42682173 | PubTator, text mining | PubMed |
| Neuromedin U 'innervation' reprograms myeloid immunosuppression in neuroendocrine prostate cancer. | Oncogene | 2026 | 42675222 | PubTator, text mining | PubMed |
| T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia. | Blood | 2026 | 42636161 | PubTator, text mining | PubMed |
| BioPathfinder: Evidence-guided multi-agent platform enables hypothesis discovery for CAR-T engineering. | bioRxiv | 2026 | 42619779 | PubTator, text mining | PubMed |
| Paradigm shift in the pathomechanisms and treatment of inclusion body myositis: at the crossroads of cell-autonomous muscle degeneration and immune activation. | Curr Opin Neurol | 2026 | 42615630 | PubTator, text mining | PubMed |
| Eradication of pre-clinical prostate tumors by a lentiviral vector-based immunotherapy. | Mol Ther Oncol | 2026 | 42598525 | PubTator, text mining | PubMed |
| Multiomics Dissection Reveals Natural Killer Cell-CD8+ T-cell Cooperation in Shaping an Immunostimulatory Tumor Microenvironment. | Cancer Res | 2026 | 42545372 | PubTator, text mining | PubMed |
1 to 10 of 3,260
See all 3,260 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/10219
GET https://conductscience.org/api/genes/v1/10219/patents?page=2